Cellectis (CLLS)

• Market cap: $344M
• 1 day: 2.7%
• 5 days: -4.74%
• 1 month: -8.31%
• 3 months: -28.6%
• 6 months: 14.38%
• Year to date: -28.75%
• 1 year: 165.12%
• 5 years: -84.28%
• 10 years: -86.47%
• Sector: Healthcare
• Industry: Biotechnology

About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Employees: 222